

LIGAND PHARMACEUTICALS INC  
Form SC 13G  
January 29, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No. )\*

Ligand Pharmaceuticals Inc.  
(Name of Issuer)

COMMON STOCK  
(Title and Class of Securities)

53220K207  
(CUSIP Number)

DECEMBER 31, 2006  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this  
Schedule  
is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's  
initial filing on this form with respect to the subject class of securities, and  
for any subsequent amendment containing information which would alter  
the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be  
deemed to be "filed" for the purpose of Section 18 of the Securities  
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that  
section of the Act but shall be subject to all other provisions of the Act  
(however, see the Notes).

CUSIP NO. 53220K207

1 NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only)

Eaton Vance Management 04-3101341

-----  
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(See Instructions)  
(a)   
(b)   
-----

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION  
UNITED STATES OF AMERICA

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 SOLE VOTING POWER 4,141,051 6 SHARED VOTING POWER -0- 7 SOLE DISPOSITIVE POWER 4,141,051 8 SHARED DISPOSITIVE POWER -0-

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
4,141,051

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
(See Instructions)

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
5.2%

12 TYPE OF REPORTING PERSON (See Instructions)  
IA

CUSIP NO. 53220K207

Item 1.

- (a) Name of Issuer: Ligand Pharmaceuticals Inc.
- (b) Address of Issuer's Principal Executive Offices:  
10275 Science Center Drive  
San Diego, CA 92121

Item 2.

- (a) Name of Person Filing: Eaton Vance Management
- (b) Address of Principal Business Office:  
Eaton Vance Management  
255 State Street  
Boston, MA 02109
- (c) Citizenship: UNITED STATES OF AMERICA
- (d) Title of Class of Securities: Common Stock
- (e) CUSIP Number: 53220K207

Item 3. Eligibility to file Schedule 13G:

Eaton Vance Management is an investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E).

## Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G

Item 4. Ownership.

- (a) Amount beneficially owned: 4,141,051 shares.
- (b) Percent of Class: 5.2%
- (c) For information on voting and dispositive power with above listed shares, see Items 5-8 of the Cover Page.

Item 5. Ownership of Five Percent or Less of a Class.

N/A

Item 6. Ownership of more than Five Percent on Behalf of Another Person

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on

N/A

Item 8. Identification and Classification of Members of the Group.

N/A

Item 9. Notice of Dissolution of Group.

N/A.

Item 10. Certification.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATE: January 29, 2007

Eaton Vance Management.

By:/s/ Paul M. O'Neil  
Paul M. O'Neil  
Vice President